ReviewJournal of clinical medicine2020
Vaccines and Therapies in Development for SARS-CoV-2 Infections.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ocular surface manifestations of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.PloS one · 2020Pooled it
- Article
- Strategies and Trends in COVID-19 Vaccination Delivery: What We Learn and What We May Use for the Future.Vaccines · 2023Article
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
- SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.Applied biochemistry and biotechnology · 2023Review
- Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies.ACS pharmacology & translational science · 2023Article
- An Overview of SARS-CoV-2 Molecular Diagnostics in Europe.Clinics in laboratory medicine · 2022Review
- Immunogenicity of theVaccines · 2022Article
- Structure-Guided Design of Potent Inhibitors of SARS-CoV-2 3CL Protease: Structural, Biochemical, and Cell-Based Studies.Journal of medicinal chemistry · 2021Article
- A time-resolved proteomic and prognostic map of COVID-19.Cell systems · 2021Article
- Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication.Viruses · 2021Article
- COVID-19: Myths and Reality.Biochemistry. Biokhimiia · 2021Review
- Heparan Sulfate Binding Cationic Peptides Restrict SARS-CoV-2 Entry.Pathogens (Basel, Switzerland) · 2021Article
- Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.Journal of molecular graphics & modelling · 2021Article
- NSP16 2'-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies.Viruses · 2021Review
- Dysregulation of Cell Signaling by SARS-CoV-2.Trends in microbiology · 2021Review
- Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.Journal of virology · 2021Article
- Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.Infection and drug resistance · 2021Review
- Prevalence of SARS-CoV-2 in human post-mortem ocular tissues.The ocular surface · 2021Article
- Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the outbreak, there is a great need for antiviral therapies and vaccines to treat and prevent COVID-19. In this review, we provide an overview of SARS-CoV-2 and discuss the emerging therapies and vaccines that show promise in combating COVID-19. We also highlight potential viral targets that could be exploited by researchers and drug manufacturers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.